製品番号: HY-15149

ロミデプシン

(別名: Romidepsin; FK 228; FR 901228; NSC 630176)

75 Cited Publications

カスタマーレビュー

Based on 75 publication(s) in Google Scholar

Romidepsin (FK 228) is a Histone deacetylase (HDAC) inhibitor with anti-tumor activities. Romidepsin (FK 228) inhibits HDAC1, HDAC2, HDAC4, and HDAC6 with IC₅₀s of 36 nM, 47 nM, 510 nM and 1.4 μM, respectively. Romidepsin (FK 228) is produced by Chromobacterium violaceum, induces cell G2/M phase arrest and apoptosis.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.98%
CAS 番号: 128517-07-7
分子式: C₂₄H₃₆N₄O₆S₂
分子量:540.70

保管条件:

Powder -20°C, 3 years

* The compound is unstable in solutions, freshly prepared is recommended.

Romidepsin 構造式

CAS 番号: 128517-07-7

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (75)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Romidepsin (FK 228) is a Histone deacetylase (HDAC) inhibitor with anti-tumor activities. Romidepsin (FK 228) inhibits HDAC1, HDAC2, HDAC4, and HDAC6 with IC₅₀s of 36 nM, 47 nM, 510 nM and 1.4 μM, respectively^[1]. Romidepsin (FK 228) is produced by Chromobacterium violaceum, induces cell G2/M phase arrest and apoptosis^[2].

IC₅₀ & Target^[1]

HDAC1

36 nM (IC₅₀)

HDAC2

47 nM (IC₅₀)

HDAC4

510 nM (IC₅₀)

HDAC6

14000 nM (IC₅₀)

HDAC アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	GI₅₀	2.6 nM Compound: 1, FK228	Growth inhibition of human A549 cells by sulforhodamine B colorimetric method Growth inhibition of human A549 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
A549	GI₅₀	2.6 nM Compound: 5, FK228	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 24589486]
A549	GI₅₀	2.6 nM Compound: 1; FK228	Growth inhibition of human A549 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human A549 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
A549	IC₅₀	0.025 μM Compound: FK228	Growth inhibition of human A549 cells Growth inhibition of human A549 cells	[PMID: 28814374]
ACHN	GI₅₀	20 nM Compound: 1, FK228	Growth inhibition of human ACHN cells by sulforhodamine B colorimetric method Growth inhibition of human ACHN cells by sulforhodamine B colorimetric method	[PMID: 23313638]
ACHN	GI₅₀	20 nM Compound: 5, FK228	Cytotoxicity against human ACHN cells by SRB assay Cytotoxicity against human ACHN cells by SRB assay	[PMID: 24589486]
ACHN	GI₅₀	20 nM Compound: 1; FK228	Growth inhibition of human ACHN cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human ACHN cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
DMS-114	GI₅₀	3.6 nM Compound: 1, FK228	Growth inhibition of human DMS114 cells by sulforhodamine B colorimetric method Growth inhibition of human DMS114 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
DMS-114	GI₅₀	3.6 nM Compound: 5, FK228	Cytotoxicity against human DMS114 cells by SRB assay Cytotoxicity against human DMS114 cells by SRB assay	[PMID: 24589486]
DMS-114	GI₅₀	3.6 nM Compound: 1; FK228	Growth inhibition of human DMS-114 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human DMS-114 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
DMS-273	GI₅₀	5.8 nM Compound: 1, FK228	Growth inhibition of human DMS273 cells by sulforhodamine B colorimetric method Growth inhibition of human DMS273 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
DMS-273	GI₅₀	5.8 nM Compound: 5, FK228	Cytotoxicity against human DMS273 cells by SRB assay Cytotoxicity against human DMS273 cells by SRB assay	[PMID: 24589486]
DMS-273	GI₅₀	5.8 nM Compound: 1; FK228	Growth inhibition of human DMS-273 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human DMS-273 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
DU-145	GI₅₀	2.55 nM Compound: 1, FK228	Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay	[PMID: 26331334]
DU-145	GI₅₀	6 nM Compound: 1, FK228	Growth inhibition of human DU145 cells by sulforhodamine B colorimetric method Growth inhibition of human DU145 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
DU-145	GI₅₀	6 nM Compound: 5, FK228	Cytotoxicity against human DU145 cells by SRB assay Cytotoxicity against human DU145 cells by SRB assay	[PMID: 24589486]
DU-145	GI₅₀	6 nM Compound: 1; FK228	Growth inhibition of human DU-145 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human DU-145 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
HCC 2998	GI₅₀	3.1 nM Compound: 1, FK228	Growth inhibition of human HCC2998 cells by sulforhodamine B colorimetric method Growth inhibition of human HCC2998 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
HCC 2998	GI₅₀	3.1 nM Compound: 5, FK228	Cytotoxicity against human HCC2998 cells by SRB assay Cytotoxicity against human HCC2998 cells by SRB assay	[PMID: 24589486]
HCC 2998	GI₅₀	3.1 nM Compound: 1; FK228	Growth inhibition of human HCC 2998 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human HCC 2998 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
HCT-116	GI₅₀	11.6 nM Compound: FK228	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 31057733]
HCT-116	GI₅₀	3.1 nM Compound: 1, FK228	Growth inhibition of human HCT116 cells by sulforhodamine B colorimetric method Growth inhibition of human HCT116 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
HCT-116	GI₅₀	3.1 nM Compound: 5, FK228	Cytotoxicity against human HCT116 cells by SRB assay Cytotoxicity against human HCT116 cells by SRB assay	[PMID: 24589486]
HCT-116	GI₅₀	3.1 nM Compound: 1; FK228	Growth inhibition of human HCT-116 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human HCT-116 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
HCT-116	IC₅₀	0.028 μM Compound: Romidepsin	Antiproliferative activity against human HCT116 cells assessed as cell viability incubated for 72 hrs by coulter counter method Antiproliferative activity against human HCT116 cells assessed as cell viability incubated for 72 hrs by coulter counter method	[PMID: 26481659]
HCT-116	IC₅₀	3 nM Compound: FK228	Antiproliferative activity against human HCT116 cells after 48 hrs in presence of DTT by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs in presence of DTT by MTT assay	[PMID: 25147612]
HCT-15	GI₅₀	450 nM Compound: 1, FK228	Growth inhibition of human HCT15 cells by sulforhodamine B colorimetric method Growth inhibition of human HCT15 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
HCT-15	GI₅₀	450 nM Compound: 5, FK228	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 24589486]
HCT-15	GI₅₀	450 nM Compound: 1; FK228	Growth inhibition of human HCT-15 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human HCT-15 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
HCT-15	GI₅₀	450 nM Compound: 2; FK228	Cytotoxicity against human HCT-15 cells assessed as cell growth inhibition by sulforhodamine B colorimetric method Cytotoxicity against human HCT-15 cells assessed as cell growth inhibition by sulforhodamine B colorimetric method	[PMID: 34826681]
HEK293	CC₅₀	0.004 μM Compound: Romidepsin	Cytotoxicity against HEK293 cells assessed as reduction in cell growth incubated for 48 hrs by MTS assay Cytotoxicity against HEK293 cells assessed as reduction in cell growth incubated for 48 hrs by MTS assay	[PMID: 30973727]
HEK293	IC₅₀	<=0.001 μM Compound: 11; FK228	Cytotoxicity against HEK293 cells after 48 hrs by resazurin assay Cytotoxicity against HEK293 cells after 48 hrs by resazurin assay	[PMID: 28241112]
HEK293	IC₅₀	<=1 nM Compound: Romidepsin	Cytotoxicity against HEK293 cells after 48 hrs by resazurin dye based assay Cytotoxicity against HEK293 cells after 48 hrs by resazurin dye based assay	[PMID: 30245402]
HepG2	CC₅₀	0.01 μM Compound: Romidepsin	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by CellTiter-Glo assay Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by CellTiter-Glo assay	[PMID: 30973727]
HepG2	IC₅₀	2.4 ng/mL Compound: FK228; 2	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 3 days by trypan blue assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 3 days by trypan blue assay	[PMID: 35586423]
HT-29	GI₅₀	3.3 nM Compound: 1, FK228	Growth inhibition of human HT-29 cells by sulforhodamine B colorimetric method Growth inhibition of human HT-29 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
HT-29	GI₅₀	3.3 nM Compound: 5, FK228	Cytotoxicity against human HT-29 cells by SRB assay Cytotoxicity against human HT-29 cells by SRB assay	[PMID: 24589486]
HT-29	GI₅₀	3.3 nM Compound: 1; FK228	Growth inhibition of human HT-29 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human HT-29 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
IGROV-1	IC₅₀	0.08 μM Compound: Romidepsin	Antiproliferative activity against human IGROV1/Pt1 cells assessed as cell viability incubated for 72 hrs by coulter counter method Antiproliferative activity against human IGROV1/Pt1 cells assessed as cell viability incubated for 72 hrs by coulter counter method	[PMID: 26481659]
IGROV-1	IC₅₀	0.22 μM Compound: Romidepsin	Antiproliferative activity against human IGROV1 cells assessed as cell viability incubated for 72 hrs by coulter counter method Antiproliferative activity against human IGROV1 cells assessed as cell viability incubated for 72 hrs by coulter counter method	[PMID: 26481659]
KM12	GI₅₀	3.4 nM Compound: 1, FK228	Growth inhibition of human KM12 cells by sulforhodamine B colorimetric method Growth inhibition of human KM12 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
KM12	GI₅₀	3.4 nM Compound: 5, FK228	Cytotoxicity against human KM12 cells by SRB assay Cytotoxicity against human KM12 cells by SRB assay	[PMID: 24589486]
KM12	GI₅₀	3.4 nM Compound: 1; FK228	Growth inhibition of human KM12 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human KM12 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
LOX IMVI	GI₅₀	2.5 nM Compound: 1, FK228	Growth inhibition of human LOXIMVI cells by sulforhodamine B colorimetric method Growth inhibition of human LOXIMVI cells by sulforhodamine B colorimetric method	[PMID: 23313638]
LOX IMVI	GI₅₀	2.5 nM Compound: 5, FK228	Cytotoxicity against human LOXIMVI cells by SRB assay Cytotoxicity against human LOXIMVI cells by SRB assay	[PMID: 24589486]
LOX IMVI	GI₅₀	2.5 nM Compound: 1; FK228	Growth inhibition of human LOX IMVI cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human LOX IMVI cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
MCF7	GI₅₀	4.2 nM Compound: 1, FK228	Growth inhibition of human MCF7 cells by sulforhodamine B colorimetric method Growth inhibition of human MCF7 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
MCF7	GI₅₀	4.2 nM Compound: 5, FK228	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 24589486]
MCF7	GI₅₀	4.2 nM Compound: 1; FK228	Growth inhibition of human MCF7 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
MCF7	IC₅₀	0.75 nM Compound: FK-228	Growth inhibition of MCF7 cells Growth inhibition of MCF7 cells	[PMID: 17958342]
MDA-MB-231	GI₅₀	11.5 nM Compound: FK228	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 31057733]
MDA-MB-231	GI₅₀	5.5 nM Compound: 1, FK228	Growth inhibition of human MDA-MB-231 cells by sulforhodamine B colorimetric method Growth inhibition of human MDA-MB-231 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
MDA-MB-231	GI₅₀	5.5 nM Compound: 5, FK228	Cytotoxicity against human MDA-MB-231 cells by SRB assay Cytotoxicity against human MDA-MB-231 cells by SRB assay	[PMID: 24589486]
MDA-MB-231	GI₅₀	5.5 nM Compound: 1; FK228	Growth inhibition of human MDA-MB-231 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-231 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
MDA-MB-231	GI₅₀	9.7 nM Compound: 2	Antiproliferative activity against triple-negative human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay Antiproliferative activity against triple-negative human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay	[PMID: 33745280]
MKN-1	GI₅₀	3.2 nM Compound: 1, FK228	Growth inhibition of human MKN1 cells by sulforhodamine B colorimetric method Growth inhibition of human MKN1 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
MKN-1	GI₅₀	3.2 nM Compound: 5, FK228	Cytotoxicity against human MKN1 cells by SRB assay Cytotoxicity against human MKN1 cells by SRB assay	[PMID: 24589486]
MKN-1	GI₅₀	3.2 nM Compound: 1; FK228	Growth inhibition of human MKN-1 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human MKN-1 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
MKN-28	GI₅₀	17 nM Compound: 1, FK228	Growth inhibition of human MKN28 cells by sulforhodamine B colorimetric method Growth inhibition of human MKN28 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
MKN-28	GI₅₀	17 nM Compound: 5, FK228	Cytotoxicity against human MKN28 cells by SRB assay Cytotoxicity against human MKN28 cells by SRB assay	[PMID: 24589486]
MKN-28	GI₅₀	17 nM Compound: 1; FK228	Growth inhibition of human MKN-28 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human MKN-28 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
MKN-45	GI₅₀	14 nM Compound: 1, FK228	Growth inhibition of human MKN45 cells by sulforhodamine B colorimetric method Growth inhibition of human MKN45 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
MKN-45	GI₅₀	14 nM Compound: 5, FK228	Cytotoxicity against human MKN45 cells by SRB assay Cytotoxicity against human MKN45 cells by SRB assay	[PMID: 24589486]
MKN-45	GI₅₀	14 nM Compound: 1; FK228	Growth inhibition of human MKN-45 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human MKN-45 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
MKN-7	GI₅₀	4.9 nM Compound: 1, FK228	Growth inhibition of human MKN7 cells by sulforhodamine B colorimetric method Growth inhibition of human MKN7 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
MKN-7	GI₅₀	4.9 nM Compound: 5, FK228	Cytotoxicity against human MKN7 cells by SRB assay Cytotoxicity against human MKN7 cells by SRB assay	[PMID: 24589486]
MKN-7	GI₅₀	4.9 nM Compound: 1; FK228	Growth inhibition of human MKN-7 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human MKN-7 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
MKN-74	GI₅₀	3 nM Compound: 1, FK228	Growth inhibition of human MKN74 cells by sulforhodamine B colorimetric method Growth inhibition of human MKN74 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
MKN-74	GI₅₀	3 nM Compound: 5, FK228	Cytotoxicity against human MKN74 cells by SRB assay Cytotoxicity against human MKN74 cells by SRB assay	[PMID: 24589486]
MKN-74	GI₅₀	3 nM Compound: 1; FK228	Growth inhibition of human MKN-74 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human MKN-74 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
MOLT-4	GI₅₀	2.06 nM Compound: 1, FK228	Antiproliferative activity against human MOLT4 cells after 72 hrs by CCK8 assay Antiproliferative activity against human MOLT4 cells after 72 hrs by CCK8 assay	[PMID: 26331334]
NCI-H226	GI₅₀	8.9 nM Compound: 1, FK228	Growth inhibition of human NCI-H226 cells by sulforhodamine B colorimetric method Growth inhibition of human NCI-H226 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
NCI-H226	GI₅₀	8.9 nM Compound: 5, FK228	Cytotoxicity against human NCI-H226 cells by SRB assay Cytotoxicity against human NCI-H226 cells by SRB assay	[PMID: 24589486]
NCI-H226	GI₅₀	8.9 nM Compound: 1; FK228	Growth inhibition of human NCI-H226 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H226 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
NCI-H23	GI₅₀	4.6 nM Compound: 1, FK228	Growth inhibition of human NCI-H23 cells by sulforhodamine B colorimetric method Growth inhibition of human NCI-H23 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
NCI-H23	GI₅₀	4.6 nM Compound: 5, FK228	Cytotoxicity against human NCI-H23 cells by SRB assay Cytotoxicity against human NCI-H23 cells by SRB assay	[PMID: 24589486]
NCI-H23	GI₅₀	4.6 nM Compound: 1; FK228	Growth inhibition of human NCI-H23 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H23 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
NCI-H460	GI₅₀	3 nM Compound: 1, FK228	Growth inhibition of human NCI-H460 cells by sulforhodamine B colorimetric method Growth inhibition of human NCI-H460 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
NCI-H460	GI₅₀	3 nM Compound: 5, FK228	Cytotoxicity against human NCI-H460 cells by SRB assay Cytotoxicity against human NCI-H460 cells by SRB assay	[PMID: 24589486]
NCI-H460	GI₅₀	3 nM Compound: 1; FK228	Growth inhibition of human NCI-H460 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
NCI-H522	GI₅₀	1.8 nM Compound: 1, FK228	Growth inhibition of human NCI-H522 cells by sulforhodamine B colorimetric method Growth inhibition of human NCI-H522 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
NCI-H522	GI₅₀	1.8 nM Compound: 5, FK228	Cytotoxicity against human NCI-H522 cells by SRB assay Cytotoxicity against human NCI-H522 cells by SRB assay	[PMID: 24589486]
NCI-H522	GI₅₀	1.8 nM Compound: 1; FK228	Growth inhibition of human NCI-H522 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H522 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
NCI-H522	GI₅₀	1.8 nM Compound: 2; FK228	Cytotoxicity against human NCI-H522 cells assessed as cell growth inhibition by sulforhodamine B colorimetric method Cytotoxicity against human NCI-H522 cells assessed as cell growth inhibition by sulforhodamine B colorimetric method	[PMID: 34826681]
NFF	IC₅₀	<=0.001 μM Compound: 11; FK228	Cytotoxicity against human NFF cells after 72 hrs by SRB assay Cytotoxicity against human NFF cells after 72 hrs by SRB assay	[PMID: 28241112]
NFF	IC₅₀	<=1 nM Compound: Romidepsin	Cytotoxicity against human NFF cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human NFF cells after 72 hrs by sulforhodamine B assay	[PMID: 30245402]
NFF	IC₅₀	0.001 μM Compound: Romidepsin	Cytotoxicity against human NFF cells incubated for 72 hrs by SRB assay Cytotoxicity against human NFF cells incubated for 72 hrs by SRB assay	[PMID: 39208744]
OVCAR-3	GI₅₀	4.6 nM Compound: 1, FK228	Growth inhibition of human OVCAR3 cells by sulforhodamine B colorimetric method Growth inhibition of human OVCAR3 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
OVCAR-3	GI₅₀	4.6 nM Compound: 5, FK228	Cytotoxicity against human OVCAR3 cells by SRB assay Cytotoxicity against human OVCAR3 cells by SRB assay	[PMID: 24589486]
OVCAR-3	GI₅₀	4.6 nM Compound: 1; FK228	Growth inhibition of human OVCAR-3 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR-3 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
OVCAR-4	GI₅₀	20 nM Compound: 1, FK228	Growth inhibition of human OVCAR4 cells by sulforhodamine B colorimetric method Growth inhibition of human OVCAR4 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
OVCAR-4	GI₅₀	20 nM Compound: 5, FK228	Cytotoxicity against human OVCAR4 cells by SRB assay Cytotoxicity against human OVCAR4 cells by SRB assay	[PMID: 24589486]
OVCAR-4	GI₅₀	20 nM Compound: 1; FK228	Growth inhibition of human OVCAR-4 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR-4 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
OVCAR-5	GI₅₀	2.8 nM Compound: 1, FK228	Growth inhibition of human OVCAR5 cells by sulforhodamine B colorimetric method Growth inhibition of human OVCAR5 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
OVCAR-5	GI₅₀	2.8 nM Compound: 5, FK228	Cytotoxicity against human OVCAR5 cells by SRB assay Cytotoxicity against human OVCAR5 cells by SRB assay	[PMID: 24589486]
OVCAR-5	GI₅₀	2.8 nM Compound: 1; FK228	Growth inhibition of human OVCAR-5 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR-5 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
OVCAR-8	GI₅₀	5.5 nM Compound: 1, FK228	Growth inhibition of human OVCAR8 cells by sulforhodamine B colorimetric method Growth inhibition of human OVCAR8 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
OVCAR-8	GI₅₀	5.5 nM Compound: 5, FK228	Cytotoxicity against human OVCAR8 cells by SRB assay Cytotoxicity against human OVCAR8 cells by SRB assay	[PMID: 24589486]
OVCAR-8	GI₅₀	5.5 nM Compound: 1; FK228	Growth inhibition of human OVCAR-8 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR-8 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
PC-3	GI₅₀	18 nM Compound: 1, FK228	Growth inhibition of human PC3 cells by sulforhodamine B colorimetric method Growth inhibition of human PC3 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
PC-3	GI₅₀	18 nM Compound: 5, FK228	Cytotoxicity against human PC3 cells by SRB assay Cytotoxicity against human PC3 cells by SRB assay	[PMID: 24589486]
PC-3	GI₅₀	18 nM Compound: 1; FK228	Growth inhibition of human PC-3 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human PC-3 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
RXF 631	GI₅₀	6.6 nM Compound: 1, FK228	Growth inhibition of human RXF631L cells by sulforhodamine B colorimetric method Growth inhibition of human RXF631L cells by sulforhodamine B colorimetric method	[PMID: 23313638]
RXF 631	GI₅₀	6.6 nM Compound: 5, FK228	Cytotoxicity against human RXF631L cells by SRB assay Cytotoxicity against human RXF631L cells by SRB assay	[PMID: 24589486]
RXF 631	GI₅₀	6.6 nM Compound: 1; FK228	Growth inhibition of human RXF 631 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human RXF 631 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
SF-268	GI₅₀	4.9 nM Compound: 1, FK228	Growth inhibition of human SF268 cells by sulforhodamine B colorimetric method Growth inhibition of human SF268 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
SF-268	GI₅₀	4.9 nM Compound: 5, FK228	Cytotoxicity against human SF268 cells by SRB assay Cytotoxicity against human SF268 cells by SRB assay	[PMID: 24589486]
SF-268	GI₅₀	4.9 nM Compound: 1; FK228	Growth inhibition of human SF-268 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human SF-268 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
SF-295	GI₅₀	4 nM Compound: 1, FK228	Growth inhibition of human SF295 cells by sulforhodamine B colorimetric method Growth inhibition of human SF295 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
SF-295	GI₅₀	4 nM Compound: 5, FK228	Cytotoxicity against human SF295 cells by SRB assay Cytotoxicity against human SF295 cells by SRB assay	[PMID: 24589486]
SF-295	GI₅₀	4 nM Compound: 1; FK228	Growth inhibition of human SF-295 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human SF-295 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
SF-539	GI₅₀	3.6 nM Compound: 1, FK228	Growth inhibition of human SF539 cells by sulforhodamine B colorimetric method Growth inhibition of human SF539 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
SF-539	GI₅₀	3.6 nM Compound: 5, FK228	Cytotoxicity against human SF539 cells by SRB assay Cytotoxicity against human SF539 cells by SRB assay	[PMID: 24589486]
SF-539	GI₅₀	3.6 nM Compound: 1; FK228	Growth inhibition of human SF-539 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human SF-539 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
Sf9	IC₅₀	0.0024 μM Compound: FK228	Inhibition of human recombinant C-terminal FLAG/His-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells after 1 hr by HDAC-Glo1/2 luminescent assay Inhibition of human recombinant C-terminal FLAG/His-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells after 1 hr by HDAC-Glo1/2 luminescent assay	[PMID: 31057733]
Sf9	IC₅₀	0.0091 μM Compound: FK228	Inhibition of human recombinant C-terminal FLAG-tagged HDAC6 expressed in baculovirus infected Sf9 insect cells after 1 hr by HDAC-Glo1/2 luminescent assay Inhibition of human recombinant C-terminal FLAG-tagged HDAC6 expressed in baculovirus infected Sf9 insect cells after 1 hr by HDAC-Glo1/2 luminescent assay	[PMID: 31057733]
Sf9	IC₅₀	4.462 μM Compound: FK228	Inhibition of human recombinant C-terminal GST-tagged HDAC4 (101 to 1084 residues) expressed in baculovirus infected Sf9 insect cells after 1 hr by HDAC-Glo1/2 luminescent assay Inhibition of human recombinant C-terminal GST-tagged HDAC4 (101 to 1084 residues) expressed in baculovirus infected Sf9 insect cells after 1 hr by HDAC-Glo1/2 luminescent assay	[PMID: 31057733]
SK-OV-3	GI₅₀	3.3 nM Compound: 1, FK228	Growth inhibition of human SKOV3 cells by sulforhodamine B colorimetric method Growth inhibition of human SKOV3 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
SK-OV-3	GI₅₀	3.3 nM Compound: 5, FK228	Cytotoxicity against human SKOV3 cells by SRB assay Cytotoxicity against human SKOV3 cells by SRB assay	[PMID: 24589486]
SK-OV-3	GI₅₀	3.3 nM Compound: 1; FK228	Growth inhibition of human SK-OV-3 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human SK-OV-3 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
SNB-75	GI₅₀	7.2 nM Compound: 1, FK228	Growth inhibition of human SNB75 cells by sulforhodamine B colorimetric method Growth inhibition of human SNB75 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
SNB-75	GI₅₀	7.2 nM Compound: 5, FK228	Cytotoxicity against human SNB75 cells by SRB assay Cytotoxicity against human SNB75 cells by SRB assay	[PMID: 24589486]
SNB-75	GI₅₀	7.2 nM Compound: 1; FK228	Growth inhibition of human SNB-75 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human SNB-75 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
SNB-78	GI₅₀	9.6 nM Compound: 1, FK228	Growth inhibition of human SNB78 cells by sulforhodamine B colorimetric method Growth inhibition of human SNB78 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
SNB-78	GI₅₀	9.6 nM Compound: 5, FK228	Cytotoxicity against human SNB78 cells by SRB assay Cytotoxicity against human SNB78 cells by SRB assay	[PMID: 24589486]
SNB-78	GI₅₀	9.6 nM Compound: 1; FK228	Growth inhibition of human SNB-78 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human SNB-78 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
St-4	GI₅₀	22 nM Compound: 1, FK228	Growth inhibition of human St-4 cells by sulforhodamine B colorimetric method Growth inhibition of human St-4 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
St-4	GI₅₀	22 nM Compound: 5, FK228	Cytotoxicity against human St-4 cells by SRB assay Cytotoxicity against human St-4 cells by SRB assay	[PMID: 24589486]
St-4	GI₅₀	22 nM Compound: 1; FK228	Growth inhibition of human St-4 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human St-4 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
T-cell	EC₅₀	0.003 μM Compound: Romidepsin, istodax	Reactivation of latent HIV1 NL4-3-Luc expression in human naive CD4+ T cells treated 7 days post-infection measured after 48 hrs by luminescence plate reader analysis Reactivation of latent HIV1 NL4-3-Luc expression in human naive CD4+ T cells treated 7 days post-infection measured after 48 hrs by luminescence plate reader analysis	[PMID: 24495105]
U-251	GI₅₀	3.9 nM Compound: 1, FK228	Growth inhibition of human U251 cells by sulforhodamine B colorimetric method Growth inhibition of human U251 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
U-251	GI₅₀	3.9 nM Compound: 5, FK228	Cytotoxicity against human U251 cells by SRB assay Cytotoxicity against human U251 cells by SRB assay	[PMID: 24589486]
U-251	GI₅₀	3.9 nM Compound: 1; FK228	Growth inhibition of human U-251 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human U-251 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27318982]
U-937	CC₅₀	0.73 nM Compound: Romidepsin	Cytotoxicity against human U937 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human U937 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 29541372]
U-937	GI₅₀	3.41 nM Compound: 1, FK228	Antiproliferative activity against human U937 cells after 72 hrs by CCK8 assay Antiproliferative activity against human U937 cells after 72 hrs by CCK8 assay	[PMID: 26331334]
WI-38	GI₅₀	30.1 nM Compound: 2	Cytotoxicity against human WI-38 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay Cytotoxicity against human WI-38 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay	[PMID: 33745280]
WI-38	GI₅₀	5.39 nM Compound: 1, FK228	Antiproliferative activity against human WI38 cells after 72 hrs by CCK8 assay Antiproliferative activity against human WI38 cells after 72 hrs by CCK8 assay	[PMID: 26331334]

体外実験

Romidepsin (0-72 hours; 0-80 nM) inhibits proliferation of HCC cells in dose-dependent manner^[2].
Romidepsin (0-48 hours; 0-60 nM) leads to a time- and dose-dependent induction of cell cycle arrest in the G2/M phase in HCC cells^[2].
Romidepsin (0-48 hours; 0-60 nM) promotesapoptosis in HCC cells, increases c-caspase-3, c-caspase-9, and c-PARP protein expression^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:

HCC cells
Concentration:

0 nM; 10 nM; 20 nM; 30 nM; 40 nM; 50 nM; 60 nM; 70 nM; 80 nM
Incubation Time:

0 hours; 12 hours; 24 hours; 48 hours; 72 hours
Result:

Inhibited HCC cells proliferation.

Cell Cycle Analysis^[2]

Cell Line:

HCC cells
Concentration:

0 nM; 15 nM; 30 nM; 60 nM
Incubation Time:

12 hours;24 hours; 48 hours
Result:

Caused a G2/M arrest.

Western Blot Analysis^[2]

Cell Line:

HCC cells
Concentration:

0 nM; 15 nM; 30 nM; 60 nM
Incubation Time:

12 hours;24 hours; 48 hours
Result:

Increaesd c-caspase-3, c-caspase-9, and c-PARP expression in HCC cells.

体内実験

Romidepsin (intraperitoneal injection; 0.5 and 1 mg/kg; every 3 day; 21 days) inhibited the tumor growth, reveals a higher expression of p-cdc25C, ki67, c-caspase-3 and c-PARP, and a lower expression of Ki-67 in Romidepsin treated tumors ^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Nude mice with Huh7 cells^[2]
Dosage:

0.5 and 1 mg/kg
Administration:

Intraperitoneal injection; 0.5 and 1 mg/kg; every 3 day; 21 days
Result:

Suppressed tumor growth in mouse xenograft models.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 128517-07-7
性状 Solid
分子量 540.70
分子式 C₂₄H₃₆N₄O₆S₂
Color White to off-white
SMILES

C/C=C(NC([C@@H](CSSCC/C=C/[C@@H](O1)CC2=O)NC([C@@H](C(C)C)N2)=O)=O)/C(N[C@@H](C(C)C)C1=O)=O
別名

Romidepsin; FK 228; FR 901228; NSC 630176
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years

* The compound is unstable in solutions, freshly prepared is recommended.

Publications (75)

All WBCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

2026 Jun 5;11(1):218.
Signal Transduct Target Ther

The noncanonical function of liver-type phosphofructokinase potentiates the efficacy of HDAC inhibitors in cancer. [Abstract]

2025 Oct 14;10(1):341. PMID: 41083431
Cancer Cell

Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer. [Abstract]

2023 Mar 13;41(3):602-619.e11. PMID: 36868226

Romidepsin purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2023 Mar 13;41(3):602-619.e11. [Abstract]

The triple combination of E + R + iC significantly decreases tumor volume compared with double combinations, in mice. E: enzalutamide (30 mg/kg; p.o.; single daily for 10 days); R: Romidepsin (0.3 mg/kg; i.p.; single daily for 10 days); iC: CXCR2 inhibitor.
Cancer Discov

Divergent Evolution of Malignant Subclones Maintains a Balance Between Induced Aggressiveness and Intrinsic Drug Resistance in T Cell Cancer. [Abstract]

2025 Jun 16. PMID: 40516109
Cancer Res

Cross-talk between SOX2 and TGFβ Signaling Regulates EGFR-TKI Tolerance and Lung Cancer Dissemination. [Abstract]

2020 Oct 15;80(20):4426-4438. PMID: 32816907
Cancer Res

PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells. [Abstract]

2016 Dec 1;76(23):7001-7011. PMID: 27671680
Theranostics

HDAC1 and 2 regulate endothelial VCAM-1 expression and atherogenesis by suppressing methylation of the GATA6 promoter. [Abstract]

2021 Mar 20;11(11):5605-5619. PMID: 33859766
J Clin Invest

PROX1 is an early driver of lineage plasticity in prostate cancer. [Abstract]

2025 Jun 2;135(11):e187490. PMID: 40454483
Cell Rep Med

Modeling high-risk Wilms tumors enables the discovery of therapeutic vulnerability. [Abstract]

2024 Oct 15;5(10):101770. PMID: 39368485
Cell Death Dis

Checkpoint regulator B7x is epigenetically regulated by HDAC3 and mediates resistance to HDAC inhibitors by reprogramming the tumor immune environment in colorectal cancer. [Abstract]

2020 Sep 15;11(9):753. PMID: 32934224
Cell Death Dis

Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia. [Abstract]

2020 Sep 18;11(9):778. PMID: 32948748
Cancer Lett

HOX code-based stratification reveals RUNX1T1-HDAC reprogramming as a targetable driver of lineage plasticity across cancers. [Abstract]

2026 Mar 28:218465. PMID: 41912135
Cancer Lett

High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1/BCL-XL inhibition against Ewing sarcoma. [Abstract]

2023 Feb 1:554:216028. PMID: 36462556
EBioMedicine

Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma. [Abstract]

2023 Jan:87:104420. PMID: 36592514
Acta Pharmacol Sin

FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11. [Abstract]

2022 Aug;43(8):2119-2127. PMID: 34893686
NPJ Precis Oncol

Optimized culturing yields high success rates and preserves molecular heterogeneity, enabling personalized screening for high-grade gliomas. [Abstract]

2025 May 27;9(1):156. PMID: 40425813
NPJ Precis Oncol

Cytokine and epigenetic regulation of CEACAM6 mediates EGFR-driven signaling and drug response in lung adenocarcinoma. [Abstract]

2025 Apr 22;9(1):115. PMID: 40263546
Apoptosis

Valproic acid upregulates the expression of the p75NTR/sortilin receptor complex to induce neuronal apoptosis. [Abstract]

2020 Oct;25(9-10):697-714. PMID: 32712736
Mol Med

FK228 suppress the growth of human malignant pleural mesothelioma tumor independent to epithelioid or non-epithelioid histology. [Abstract]

2024 May 31;30(1):73. PMID: 38822233
Mol Med

iNOS/NO is required for IRF1 activation in response to liver ischemia-reperfusion in mice. [Abstract]

2020 Jun 9;26(1):56. PMID: 32517688
Clin Transl Med

DNTTIP1 drives leukaemogenesis through MiDAC-mediated epigenetic silencing of BMF. [Abstract]

2026 Feb;16(2):e70603. PMID: 41603084
Clin Transl Med

LncRNA LINC00942 promotes chemoresistance in gastric cancer by suppressing MSI2 degradation to enhance c-Myc mRNA stability. [Abstract]

2022 Jan;12(1):e703. PMID: 35073459
Blood Adv

BH3 mimetic drugs overcome the microenvironment-induced resistance to crizotinib in ALK+ anaplastic large cell lymphoma. [Abstract]

2025 Jul 2:bloodadvances.2024015322. PMID: 40601898
J Med Chem

Discovery of a Novel Benzimidazole Derivative Targeting Histone Deacetylase to Induce Ferroptosis and Trigger Immunogenic Cell Death. [Abstract]

2024 Sep 12;67(17):15098-15117. PMID: 39145486
J Med Chem

Gnidimacrin, a Potent Anti-HIV Diterpene, Can Eliminate Latent HIV-1 Ex Vivo by Activation of Protein Kinase C β. [Abstract]

2015 Nov 12;58(21):8638-46. PMID: 26509731
Mol Cancer Ther

Functional genomics and proteomics identify Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in diverse T-cell lymphoma models. [Abstract]

2026 Jun 13. PMID: 42295240
Cells

Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems. [Abstract]

2020 Jul 10;9(7):1661. PMID: 32664214
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Commun Biol

LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer. [Abstract]

2021 Oct 29;4(1):1235. PMID: 34716410

Romidepsin purchased from MedChemExpress. Usage Cited in: Commun Biol. 2021 Oct 29;4(1):1235. [Abstract]

TNBC model cells (MDA-MB-231 and BT-549) were treated with indicated HDACi (Vorinostat: 10 µM; Panobinostat: 1 µM; Romidepsin: 1 µM; Givinostat: 1 µM) for 24 h and expression of LIFR, p-STAT3(Y705), and STAT3 were determined using Western blotting.
Clin Epigenetics

Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide. [Abstract]

2023 Feb 6;15(1):19. PMID: 36740715
Toxicol Sci

Prenatal Dexamethasone Exposure Induced Alterations in Neurobehavior and Hippocampal Glutamatergic System Balance in Female Rat Offspring. [Abstract]

2019 Oct 1;171(2):369-384. PMID: 31518422
Eur J Pharm Sci

Enhancement of the in vitro anti-leukemic effect of the histone deacetylase inhibitor romidepsin using Poly-(D, L-lactide-co-glycolide) nanoparticles as a drug carrier. [Abstract]

2025 Apr 1:207:107043. PMID: 39952370
Mol Med Rep

H3K14 hyperacetylation‑mediated c‑Myc binding to the miR‑30a‑5p gene promoter under hypoxia postconditioning protects senescent cardiomyocytes from hypoxia/reoxygenation injury. [Abstract]

2021 Jun;23(6):468. PMID: 33880587
Sci Rep

Disruption of zinc homeostasis reduces histone acetylation levels in normal and tumor cells. [Abstract]

2026 Jan 10;16(1):4983. PMID: 41519875
PLoS Pathog

Chromatin remodeling controls Kaposi's sarcoma-associated herpesvirus reactivation from latency. [Abstract]

2018 Sep 13;14(9):e1007267. PMID: 30212584

Romidepsin purchased from MedChemExpress. Usage Cited in: PLoS Pathog. 2018 Sep 13;14(9):e1007267. [Abstract]

Immunoblot analysis for vIL-6, ORF45, or actin is performed on lysates from BCBL-1 cells treated with NaB+TPA, Romidepsin or LBH589.
Neoplasia

Acquired vulnerability against EGF receptor inhibition in gastric cancer promoted by class I histone deacetylase inhibitor entinostat. [Abstract]

2025 Feb:60:101121. PMID: 39864337
Stem Cells

Cytokine and epigenetic regulation of programmed death-ligand 1 in stem cell differentiation and cancer cell plasticity. [Abstract]

2021 Oct;39(10):1298-1309. PMID: 34182610
Cancers (Basel)

Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy. [Abstract]

2019 Sep 7;11(9):1327. PMID: 31500290
J Cell Mol Med

Inactivation of CDK12 Enhances Mitochondrial Efficiency to Suppress DNA Damage. [Abstract]

2026 Apr;30(7):e71101. PMID: 41896195
Neurooncol Adv

Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma. [Abstract]

2021 Jul 17;3(1):vdab099. PMID: 34485908
Epigenetics Chromatin

Ovulatory signal-triggered chromatin remodeling in ovarian granulosa cells by HDAC2 phosphorylation activation-mediated histone deacetylation. [Abstract]

2023 Apr 19;16(1):11. PMID: 37076890
J Pharmacol Exp Ther

Downregulation of TrkB Expression and Signaling by Valproic Acid and Other Histone Deacetylase Inhibitors. [Abstract]

2019 Sep;370(3):490-503. PMID: 31308194
Cancer Res Commun

Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells. [Abstract]

2025 Jun 1;5(6):1034-1048. PMID: 40478628
Cancer Res Commun

Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress. [Abstract]

2023 Aug 17;3(8):1580-1593. PMID: 37599787
ACS Med Chem Lett

Elimination of HIV-1 Latently Infected Cells by Gnidimacrin and a Selective HDAC Inhibitor. [Abstract]

2018 Feb 6;9(3):268-273. PMID: 29541372
Tumour Virus Res

Targeting EBV-associated gastric cancer by lytic induction therapy with nanatinostat. [Abstract]

2026 Jun 27:22:200346. PMID: 42364907
Mol Carcinog

BTG1 Acts as a Critical Tumor Suppressor Link Between HDAC Inhibition and β-Catenin Signaling Suppression in Diffuse Large B-Cell Lymphoma. [Abstract]

2026 Jun;65(6):754-769. PMID: 41950351
Int J Parasitol Drugs Drug Resist

2026 May 17;31:100649.
Arch Biochem Biophys

TET3 inhibits the decidualization of human endometrial stromal cells by regulating ITGA10 transcription through recruiting HDAC1/2. [Abstract]

2025 Oct:772:110552. PMID: 40675525
Cancer Med

Prognostic and Monitoring Utility of Serum CEA in Lung Adenocarcinoma: Differential Roles in EGFR-TKI and Chemotherapy Treatments. [Abstract]

2025 Sep;14(17):e71170. PMID: 40856433
Exp Cell Res

Diacylglycerol kinase γ predicts prognosis and functions as a tumor suppressor by negatively regulating glucose transporter 1 in hepatocellular carcinoma. [Abstract]

2018 Dec 15;373(1-2):211-220. PMID: 30399372
Clin Transl Immunology

Synergistic integration of histone deacetylase inhibitors apparently enhances the cytokine-induced killer cell efficiency in multiple myeloma via the NKG2D pathway. [Abstract]

2024 Mar 25;13(3):e1500. PMID: 38529413
Virus Res

Transcriptional behavior of the HIV-1 promoter in context of the BACH2 prominent proviral integration gene. [Abstract]

2021 Feb:293:198260. PMID: 33316352
Virus Res

Pinpointing recurrent proviral integration sites in new models for latent HIV-1 infection. [Abstract]

2018 Apr 2:249:69-75. PMID: 29550509
PLoS One

Targeted HIV-1 Latency Reversal Using CRISPR/Cas9-Derived Transcriptional Activator Systems. [Abstract]

2016 Jun 24;11(6):e0158294. PMID: 27341108
Neurosci Lett

Romidepsin induces caspase-dependent cell death in human neuroblastoma cells. [Abstract]

2017 Jul 13:653:12-18. PMID: 28506690

Romidepsin purchased from MedChemExpress. Usage Cited in: Neurosci Lett. 2017 Jul 13:653:12-18. [Abstract]

Romidepsin increases histone acetylation in SH-SY5Y neuroblastoma cells. Western blots of pAcH3 and β-actin levels in SH-SY5Y cells cultured for 24 h with 0-40 nM of Romidepsin. 20 nM and 40 nM Romidepsin significantly increase the levels of pAcH3 relative to control, which is measured by densitometric quantification of pAcH3 protein levels relative to β-actin loading control.
bioRxiv

2025 Oct 31.
bioRxiv

Integrating functional genomics and proteomics identifies Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in T-cell lymphoma. [Abstract]

2025 Oct 9:2025.10.08.681217. PMID: 41279001
bioRxiv

2025 May 23.
Authorea

2025 Apr 18.
bioRxiv

2025 March 12.
University of Bonn

2025.
bioRxiv

2024 September 20.
bioRxiv

A high-throughput, microplate reader-based method to monitor in vitro HIV latency reversal in the absence of flow cytometry. [Abstract]

2024 Sep 11:2024.09.11.612557. PMID: 39314410
Columbia University

2023 Aug 23.
Research Square Print

2023 Mar 9.
Authorea

2023 Feb 17.
Asian Pac J Cancer Prev

Quantitative Profiling of Alpha-Subunit of IL-3 Receptor on Single Acute Myeloid Leukemia Cells by Super-Resolution Imaging. [Abstract]

2023 Jan 1;24(1):185-194. PMID: 36708567
Research Square Print

September 13th, 2022.
Uppsala University

2022 Feb.
bioRxiv

April 22, 2021.
Research Square Preprint

2021 May.
Università degli Studi di CAGLIARI

2021 May.
Methods Mol Biol

Methods for High-throughput Drug Combination Screening and Synergy Scoring. [Abstract]

2018:1711:351-398. PMID: 29344898
Oncotarget

CBX7 is a glioma prognostic marker and induces G1/S arrest via the silencing of CCNE1. [Abstract]

2017 Apr 18;8(16):26637-26647. PMID: 28460453

溶剤 & 溶解度

体外:

DMSO : ≥ 100 mg/mL (184.95 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8495 mL

9.2473 mL

18.4945 mL

5 mM

0.3699 mL

1.8495 mL

3.6989 mL

10 mM

0.1849 mL

0.9247 mL

1.8495 mL

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (3.85 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (3.85 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (3.85 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (295 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Furumai R, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002 Sep 1;62(17):4916-21. [Content Brief]

[2]. Sun WJ, et al. Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Jun/caspase3 pathway in hepatocellular carcinoma cells. Biochem Pharmacol. 2017 Mar 1;127:90-100. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8495 mL	9.2473 mL	18.4945 mL	46.2364 mL
	5 mM	0.3699 mL	1.8495 mL	3.6989 mL	9.2473 mL
	10 mM	0.1849 mL	0.9247 mL	1.8495 mL	4.6236 mL
	15 mM	0.1233 mL	0.6165 mL	1.2330 mL	3.0824 mL
	20 mM	0.0925 mL	0.4624 mL	0.9247 mL	2.3118 mL
	25 mM	0.0740 mL	0.3699 mL	0.7398 mL	1.8495 mL
	30 mM	0.0616 mL	0.3082 mL	0.6165 mL	1.5412 mL
	40 mM	0.0462 mL	0.2312 mL	0.4624 mL	1.1559 mL
	50 mM	0.0370 mL	0.1849 mL	0.3699 mL	0.9247 mL
	60 mM	0.0308 mL	0.1541 mL	0.3082 mL	0.7706 mL
	80 mM	0.0231 mL	0.1156 mL	0.2312 mL	0.5780 mL
	100 mM	0.0185 mL	0.0925 mL	0.1849 mL	0.4624 mL

Keywords

Romidepsin

75 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

ロミデプシン

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

MedChemExpress（MCE）の使用を引用している文献 Romidepsin

HDAC アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (75)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

ロミデプシン

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

MedChemExpress（MCE）の使用を引用している文献 Romidepsin

HDAC アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (75)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Romidepsin 関連分類

HY-15149 関連分類